This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Device Drama Not Over Yet

Andrew says that St. Jude is also well-positioned in the market for neurological devices, especially with its recent purchase of Advanced Neuromodulation Systems. William Blair has received compensation or expects to be compensated by St. Jude for investment banking services.

Another way St. Jude could factor into the equation would be as a possible acquirer of assets a combined Guidant-Boston Scientific might have to shed in order to gain antitrust clearance from regulators -- although Medtronic and Abbott Labs (ABT - Get Report) could be takers, as well.

For now, Boston says its proposal for Guidant is better than J&J's and contends its offer could be closed quickly. Brozak isn't as optimistic, saying Guidant would need weeks if not months to complete its due diligence, meaning the process wouldn't be finished by the end of the year.

And at least one analyst isn't going to be entirely surprised if J&J declines to hit back at Boston Scientific.

"Given all the trials and tribulations, we doubt JNJ will attempt to make a counter offer -- but as investors have learned over the past few years to never say never," Jason Wittes of Leerink Swann wrote in a research report. A director of Guidant serves as a director of Leerink Swann, but the firm doesn't provide investment banking services for the company.

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ABT $48.32 -0.29%
BSX $18.34 -0.43%
JNJ $101.08 0.62%
MDT $77.61 -1.13%
STJ $73.47 -0.73%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs